Cargando…
Multidisciplinary Pharmacotherapeutic Options for Nonalcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are multidisciplinary liver diseases that often accompany type 2 diabetes or metabolic syndrome, which are characterized by insulin resistance. Therefore, effective treatment of type 2 diabetes and metabolic syndrome s...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3523542/ https://www.ncbi.nlm.nih.gov/pubmed/23304532 http://dx.doi.org/10.1155/2012/950693 |
_version_ | 1782253225296003072 |
---|---|
author | Nakajima, Kei |
author_facet | Nakajima, Kei |
author_sort | Nakajima, Kei |
collection | PubMed |
description | Nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are multidisciplinary liver diseases that often accompany type 2 diabetes or metabolic syndrome, which are characterized by insulin resistance. Therefore, effective treatment of type 2 diabetes and metabolic syndrome should target not only the cardiometabolic abnormalities, but also the associated liver disorders. In the last decade, it has been shown that metformin, thiazolidinediones, vitamin E, ezetimibe, n-3 polyunsaturated fatty acids, renin-angiotensin system (RAS) blockers, and antiobesity drugs may improve hepatic pathophysiological disorders as well as clinical parameters. Accordingly, insulin sensitizers, antioxidative agents, Niemann-Pick C1-like 1 (NPC1L1) inhibitors, RAS blockers, and drugs that target the central nervous system may represent candidate pharmacotherapies for NAFLD and possibly NASH. However, the efficacy, safety, and tolerability of long-term treatment (potentially for many years) with these drugs have not been fully established. Furthermore, clinical trials have not comprehensively examined the efficacy of lipid-lowering drugs (i.e., statins, fibrates, and NPC1L1 inhibitors) for the treatment of NAFLD. Although clinical evidence for RAS blockers and incretin-based agents (GLP-1 analogs and dipeptidyl peptidase-4 inhibitors) is also lacking, these agents are promising in terms of their insulin-sensitizing and anti-inflammatory effects without causing weight gain. |
format | Online Article Text |
id | pubmed-3523542 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-35235422013-01-09 Multidisciplinary Pharmacotherapeutic Options for Nonalcoholic Fatty Liver Disease Nakajima, Kei Int J Hepatol Review Article Nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are multidisciplinary liver diseases that often accompany type 2 diabetes or metabolic syndrome, which are characterized by insulin resistance. Therefore, effective treatment of type 2 diabetes and metabolic syndrome should target not only the cardiometabolic abnormalities, but also the associated liver disorders. In the last decade, it has been shown that metformin, thiazolidinediones, vitamin E, ezetimibe, n-3 polyunsaturated fatty acids, renin-angiotensin system (RAS) blockers, and antiobesity drugs may improve hepatic pathophysiological disorders as well as clinical parameters. Accordingly, insulin sensitizers, antioxidative agents, Niemann-Pick C1-like 1 (NPC1L1) inhibitors, RAS blockers, and drugs that target the central nervous system may represent candidate pharmacotherapies for NAFLD and possibly NASH. However, the efficacy, safety, and tolerability of long-term treatment (potentially for many years) with these drugs have not been fully established. Furthermore, clinical trials have not comprehensively examined the efficacy of lipid-lowering drugs (i.e., statins, fibrates, and NPC1L1 inhibitors) for the treatment of NAFLD. Although clinical evidence for RAS blockers and incretin-based agents (GLP-1 analogs and dipeptidyl peptidase-4 inhibitors) is also lacking, these agents are promising in terms of their insulin-sensitizing and anti-inflammatory effects without causing weight gain. Hindawi Publishing Corporation 2012 2012-12-09 /pmc/articles/PMC3523542/ /pubmed/23304532 http://dx.doi.org/10.1155/2012/950693 Text en Copyright © 2012 Kei Nakajima. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Nakajima, Kei Multidisciplinary Pharmacotherapeutic Options for Nonalcoholic Fatty Liver Disease |
title | Multidisciplinary Pharmacotherapeutic Options for Nonalcoholic Fatty Liver Disease |
title_full | Multidisciplinary Pharmacotherapeutic Options for Nonalcoholic Fatty Liver Disease |
title_fullStr | Multidisciplinary Pharmacotherapeutic Options for Nonalcoholic Fatty Liver Disease |
title_full_unstemmed | Multidisciplinary Pharmacotherapeutic Options for Nonalcoholic Fatty Liver Disease |
title_short | Multidisciplinary Pharmacotherapeutic Options for Nonalcoholic Fatty Liver Disease |
title_sort | multidisciplinary pharmacotherapeutic options for nonalcoholic fatty liver disease |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3523542/ https://www.ncbi.nlm.nih.gov/pubmed/23304532 http://dx.doi.org/10.1155/2012/950693 |
work_keys_str_mv | AT nakajimakei multidisciplinarypharmacotherapeuticoptionsfornonalcoholicfattyliverdisease |